More Phase III success with Amgen's biosimilar Humira
This article was originally published in Scrip
Executive Summary
A second Phase III study evaluating the efficacy and safety of Amgen's biosimilar candidate ABP 501 compared with AbbVie's Humira (adalimumab) in patients with moderate-to-severe rheumatoid arthritis has met its primary endpoint. The patents on Humira, 2013's top-selling drug, begin expiring in the major markets in 2016.